Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Rating of "Hold" by Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has earned a consensus recommendation of "Hold" from the twenty-one analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.83.

A number of research analysts have commented on SAGE shares. TD Cowen reduced their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating on the stock in a research report on Thursday. The Goldman Sachs Group cut their price target on shares of Sage Therapeutics from $19.00 to $11.00 and set a "neutral" rating for the company in a research report on Friday, July 26th. Royal Bank of Canada raised Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price objective on the stock in a research note on Thursday. Oppenheimer dropped their target price on Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Wednesday, October 30th. Finally, Scotiabank lowered their price objective on Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating for the company in a research report on Wednesday, October 30th.

Sage Therapeutics Stock Up 6.6 %

NASDAQ:SAGE traded up $0.32 during trading hours on Friday, hitting $5.17. 871,036 shares of the company's stock traded hands, compared to its average volume of 947,916. The firm has a market cap of $316.25 million, a P/E ratio of -0.93 and a beta of 0.92. The business's fifty day simple moving average is $6.70 and its two-hundred day simple moving average is $9.05. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $28.26.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The firm's revenue for the quarter was up 337.1% on a year-over-year basis. During the same quarter last year, the company posted ($2.81) earnings per share. On average, analysts expect that Sage Therapeutics will post -6.5 EPS for the current year.

Hedge Funds Weigh In On Sage Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC grew its position in shares of Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company's stock valued at $43,000 after acquiring an additional 2,782 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 4,672 shares in the last quarter. Creative Planning purchased a new position in Sage Therapeutics during the 3rd quarter valued at approximately $88,000. Lazard Asset Management LLC bought a new stake in Sage Therapeutics in the 1st quarter worth approximately $127,000. Finally, Quest Partners LLC raised its holdings in shares of Sage Therapeutics by 14.5% during the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company's stock worth $128,000 after acquiring an additional 1,486 shares in the last quarter. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.